New study checks if HER2 tests give same results across cancers

NCT ID NCT07404202

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Feb 11, 2026 · Last updated May 13, 2026 · Updated 11 times

Summary

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers want to see if different HER2 tests give the same results. No treatment is given—only existing tissue samples are analyzed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAN-TUMOR(NSCLC, GYN CANCERS, BTC AND UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Beijing, China
Research Site
WITHDRAWN

Changsha, China
Research Site
RECRUITING

Chengdu, China
Research Site
RECRUITING

Guangzhou, China
Research Site
WITHDRAWN

Guangzhou, China
Research Site
NOT_YET_RECRUITING

Guangzhou, China
Research Site
RECRUITING

Haerbin, China
Research Site
RECRUITING

Jinan, China
Research Site
RECRUITING

Nantong, China
Research Site
NOT_YET_RECRUITING

Shanghai, China
Research Site
RECRUITING

Shanghai, China
Research Site
NOT_YET_RECRUITING

Shenyang, China
Research Site
WITHDRAWN

Suzhou, China
Research Site
NOT_YET_RECRUITING

Ürümqi, China

Conditions

Explore the condition pages connected to this study.

PAN-TUMOR(NSCLC, GYN CANCERS, BTC AND UC) PAN-TUMOR(NSCLC, GYN CANCERS, BTC AND UC)